2021
DOI: 10.1353/hpu.2021.0142
|View full text |Cite
|
Sign up to set email alerts
|

Improving Access to Hepatitis C Treatment Using Clinical Pharmacist Services in an Uninsured, At-Risk Population at a Community Health Center

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Team-based models in community centres with health education and pharmaceutical expertise have evidenced accomplishments in treating HCV among uninsured populations. 46 Furthermore, trust in Clemson Rural Health and the MHCs was achieved with underserved populations through community connections and dedication to revisiting communities. Through coordination with community partners, Clemson Rural Health identified locations within underserved regions that were best suited for allocation of the MHCs.…”
Section: Discussionmentioning
confidence: 99%
“…Team-based models in community centres with health education and pharmaceutical expertise have evidenced accomplishments in treating HCV among uninsured populations. 46 Furthermore, trust in Clemson Rural Health and the MHCs was achieved with underserved populations through community connections and dedication to revisiting communities. Through coordination with community partners, Clemson Rural Health identified locations within underserved regions that were best suited for allocation of the MHCs.…”
Section: Discussionmentioning
confidence: 99%
“…Literature discusses pharmacists engaging in interprofessional care models to support adherence, side effect management, and treatment success. [38][39][40][41][42] Integration of the 340B Drug Pricing Program through HRSA 43 into pharmacies on-site or contracted with FQHCs, as well as pharmacist engagement in navigating complex insurance requirements, have facilitated access to these expensive therapies used to treat HCV and HIV. This has specifically been cited in rural and uninsured populations.…”
Section: Hepatitis C Virus and Human Immunodeficiency Virusmentioning
confidence: 99%